The first Phase III and second Phase III trials will be multi-centre, randomised, assessor-blind, active-comparator studies to determine the efficacy, safety and tolerability of orally administered Zintrodiazine
_256_384.jpg)
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
New appointments bring diagnostics and medtech expertise to strengthen healthcare delivery and policy engagement
New minimally invasive biomarker test enables earlier diagnosis and improved clinical decision-making, aligned with global guidelines
VESCOP, ENTOD Pharmaceuticals, and APTI-MSB host the event to bridge lab-to-clinic gap in eye care
The summit brought together over 150 doctors, researchers, and practitioners worldwide
Multi-stakeholder initiative highlights inclusive sports pathways, honours neurodivergent athletes, and calls for systemic reforms
Profitability came under strain. Gross profit fell to EUR 246m, with margins narrowing to 23.7% as negative product mix—particularly in Asia Pacific—weighed on performance
The Pharmaceuticals portfolio and pipeline are more promising than perhaps ever before
New facility offers genetic testing, counselling and personalised treatment plans to enable early diagnosis and precision-led care
Subscribe To Our Newsletter & Stay Updated
